GlassScriptPhysician profile
Robert S Zimmerman
NPI 1689764706
$45,041.15
in general payments reported to CMS, 2019-2025
27 companies · $5,949 in 2025
The $5,949 reported for 2025 was more than what 88% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,800 · 2020: $493 · 2021: $206 · 2022: $2,671 · 2023: $15K · 2024: $13K · 2025: $5,949.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Honoraria: $17K · Consulting Fee: $13K · Food and Beverage: $3,232 · Travel and Lodging: $302 · Education: $238.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Honoraria | $17,145.00 |
| Consulting Fee | $12,954.00 |
| Food and Beverage | $3,231.96 |
| Travel and Lodging | $301.83 |
| Education | $238.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $33,901.36 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Lifescan, INC. | $4,809.75 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $2,000.00 | 2019 | |
| Novo Nordisk INC | $1,020.33 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbott Laboratories | $618.84 | 2020-2025 | Freestyle Libre 3 |
| Averitas Pharma INC. | $484.01 | 2023-2024 | Qutenza |
| Sanofi-Aventis U.S. LLC | $403.14 | 2019-2024 | |
| Corcept Therapeutics | $376.31 | 2019-2024 | Korlym |
| Lilly USA, LLC | $203.81 | 2019-2025 | Zepbound, Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $182.02 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $164.50 | 2019 | |
| Tandem Diabetes Care, INC. | $142.43 | 2019-2020 | |
| Amryt Pharma Holdings LTD | $104.39 | 2022-2023 | Mycapssa |
| Boehringer Ingelheim Pharmaceuticals, INC. | $96.86 | 2019 | |
| Merck Sharp & Dohme LLC | $96.04 | 2019 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $90.64 | 2022 | |
| Dexcom, INC. | $55.65 | 2019-2020 | |
| Recordati_rare_diseases_inc. | $52.41 | 2022-2025 | Signifor Lar |
| Glaxosmithkline, LLC. | $46.43 | 2024 | |
| Gilead Sciences, INC. | $33.04 | 2019 | |
| Amarin Pharma, INC. | $32.23 | 2019 | |
| Janssen Scientific Affairs, LLC | $27.67 | 2020 | |
| Novartis Pharmaceuticals Corporation | $26.37 | 2022 | |
| Eusa Pharma (US) LLC | $20.28 | 2022 | |
| Aytu Biopharma, INC. | $19.43 | 2019 | |
| Grt US Holding, INC. | $18.12 | 2022 | |
| Currax Pharmaceuticals LLC | $15.09 | 2024 | Contrave |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Zimmerman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.